We aim to make a difference by providing RNA-based therapeutics to patients with genetic diseases for whom currently no treatment exists.
Latest Press Releases
Jun. 23, 2010
Prosensa and GlaxoSmithKline initiate development of four additional products
Mar. 30, 2010
Clinical development of PRO044 initiated in an open label phase I/II study
Mar. 17, 2010
Prosensa strengthens its management team - Berndt Modig appointed as Chief Financial Officer
Oct. 13, 2009
Prosensa and GlaxoSmithKline form alliance to fight Duchenne Muscular Dystrophy
Pipeline
| Compound | Discovery | Pre-clinical | Phase I / II | Phase III |
|---|---|---|---|---|
| PRO051 | finished | finished | finished | finished |
| PRO044 | finished | finished | finished | finished |
| PRO045 | finished | finished | finished | finished |
| PRO053 | finished | finished | finished | finished |
| PRO052 | finished | finished | finished | finished |
| PRO055 | finished | finished | finished | finished |
About Prosensa
Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular disorders.
RNA Modulation
RNA-modulating therapeutics provide a powerful tool for targeted modulation of gene expression. Our unique proprietary technology platform employs single-stranded RNA-based antisense oligonucleotides (AONs) to correct mutated mRNA causing life threatening disorders.
Exon Skipping
Our exon skipping technology is based on interference with exon inclusion signals during the splicing of the pre-mRNA, in order to induce the skipping of the targeted exon from the mature mRNA (messenger RNA) and to restore the level of functional transcripts.